The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1360-1366

  Bordeleau, Louise ^a   Yakubovich, Natalia ^a   Dagenais, Gilles R ^b   Rosenstock, Julio ^c   Probstfield, Jeffrey ^d   Yu, Pan Chang ^e   Ryden, Lars E ^f   Pirags, Valdis ^g   Spinas, Giatgen A ^h   Birkeland, Kare I ⁱ   Ratner, Robert E ^j   Marin Neto, Jose A ^k   Keltai, Matyas ^l   Riddle, Matthew C ^m   Bosch, Jackie ⁿ   Yusuf, Salim ^a   Gerstein, Hertzel C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF LATVIA   (Latvia)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j GEORGETOWN UNIVERSITY   (United States)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l SEMMELWEIS UNIVERSITY   (Hungary)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE TITRATION; DYSGLYCEMIA; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84899103659     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1468     Document Type: Article

References (31)

1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-221
2. Gale EA. Collateral damage: the conundrum of drug safety. Diabetologia 2009;52:1975-1982
3. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
4. Gerber M. Background review paper on total fat, fatty acid intake and cancers. Ann Nutr Metab 2009;55:140-161
5. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr 2012;107(Suppl. 2):S228-S239
6. Bosch J, Gerstein HC, Dagenais GR, et al.; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318
7. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
8. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J; Origin Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155: 26-32, 32.e1-6
9. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506
10. Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases. Diabetes Care 2013;36: 294-301
11. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-1973
12. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31
13. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011;54:1608-1614
14. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765
15. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
16. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708
17. Jiang W, Zhu Z, McGinley JN, El Bayoumy K, Manni A, Thompson HJ. Identification of a molecular signature underlying inhibition of mammary carcinoma growth by dietary N-3 fatty acids. Cancer Res 2012;72:3795-3806
18. Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care 2013;16:156-161
19. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-945 (Pubitemid 41095944)
20. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 2006;295:403-415 (Pubitemid 43144977)
21. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013;346:f3706
22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033
23. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006;29:1990-1991 (Pubitemid 44156679)
24. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-1305 (Pubitemid 40813563)
25. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46:279-284
26. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-1622
27. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancermortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-326
28. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603
29. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33
30. Goodwin PJ, Stambolic V, Lemieux J, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-220
31. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci 2012;1271:37-43